2021
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab
Kim S, Tayar J, Fu S, Ke D, Norry E, Sun A, Miller J, Hong D. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. Journal For ImmunoTherapy Of Cancer 2021, 9: e002716. PMID: 34233963, PMCID: PMC8264871, DOI: 10.1136/jitc-2021-002716.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedAntigens, NeoplasmChondrocalcinosisFemaleHumansNeoplasm ProteinsReceptors, Antigen, T-CellConceptsImmune effector cell-associated neurotoxicity syndromeCytokine release syndromeT cellsCell therapyT-cell receptor T cellsTreatment of cytokine release syndromeImmune effector cell therapiesCalcium pyrophosphate dihydrate crystalsFallopian tube cancerT-cell therapyCD4<sup>+</sup> TDeposition of calcium pyrophosphate dihydrate crystalsTCR-T cellsEffector cell therapiesAmount of IL-6Left knee arthritisPresence of calcium pyrophosphate dihydrate crystalsMAGE-A4Th17 cellsNeurotoxicity syndromeCancer responseInterleukin-17IL-6TherapyInflammatory arthritis
2017
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Kim S, Tayar J, Trinh V, Suarez-Almazor M, Garcia S, Hwu P, Johnson D, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals Of The Rheumatic Diseases 2017, 76: 2061. PMID: 28830882, DOI: 10.1136/annrheumdis-2017-211560.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritisCell Cycle CheckpointsFemaleHumansImmunosuppressive AgentsImmunotherapyMaleMiddle AgedNeoplasmsTreatment OutcomeTumor Necrosis Factor-alphaConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCheckpoint inhibitorsReceptor antibodiesAssociated with immune-related adverse eventsMild immune-related adverse eventsEffective alternative to corticosteroidsEfficacy of ICI therapyICI-induced inflammatory arthritisImmune checkpoint inhibitor therapyAnti-IL-6 receptor antibodyAlternative to corticosteroidsTreated with corticosteroidsTreated with tocilizumabTumor necrosis factor-aImmune dampening effectsInflammatory side effectsAlternative therapeutic strategiesFood and Drug AdministrationTreatment of rheumatoid arthritisJuvenile idiopathic arthritisAntitumour responseICI therapyTNFa inhibitorsCheckpoint inhibition